Myfortic (Mycophenolic Acid)

Mycophenolic acid, the active ingredient in Myfortic, is an immunosuppressant presented as a delayed‑release tablet for oral use. It is classified as an antimetabolite and is used to prevent organ rejection in patients who have undergone solid‑organ transplantation. Myfortic is marketed in the European Union and is supplied in tablet form for systemic administration.

GNH USA supplies Myfortic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Myfortic is used to prevent graft rejection by modulating the immune response in solid‑organ transplantation.

Renal transplantation: reduces the incidence of acute and chronic rejection. Heart transplantation: helps maintain graft function and lowers rejection episodes. Liver transplantation: supports long‑term graft survival by suppressing immune activation.

Myfortic may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea or vomiting - Diarrhea or abdominal discomfort - Headache - Infections such as upper respiratory tract infections - Decreased white blood cell count (leukopenia)

Serious or Rare Side Effects: - Severe neutropenia or agranulocytosis - Opportunistic infections (e.g., CMV, PCP) - Hepatic toxicity or elevated liver enzymes - Malignancies, including lymphoproliferative disorders - Life‑threatening allergic reactions (e.g., Stevens‑Johnson syndrome)

Before initiating Myfortic, clinicians should assess baseline laboratory values and consider patient‑specific risk factors.

Monitor blood counts regularly: watch for leukopenia or neutropenia. Assess renal function: adjust dose in patients with impaired clearance. Check liver enzymes: detect potential hepatic toxicity. Avoid use in pregnancy: Myfortic is contraindicated (Category X). Review concomitant medications: consider interactions that may increase toxicity. Store at ambient temperature below 25°C: keep in the original container, protect from moisture and light.

Myfortic can interact with several drugs, requiring careful management.

Major Interactions (Avoid): - Azathioprine: additive bone‑marrow suppression. - Cyclosporine or tacrolimus: increased mycophenolate exposure. - Antacids containing aluminum or magnesium: reduce absorption of mycophenolate sodium.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, monitor INR. - Live vaccines: increased risk of infection, avoid administration. - NSAIDs: may exacerbate renal toxicity, monitor renal function.